Amneal Pharmaceuticals, Inc. has grown revenue 10% a year over three years and 8.7% a year over five. Revenue growth, 3-year annual rate: +10% (Drug Manufacturers - Specialty & Generic median +13%). Revenue growth, 5-year rate: +8.7%, growth has picked up over the last three years. Years of annual history on file: 10, FY2016 to FY2025, as filed.

AMRXAmneal Pharmaceuticals, Inc.

Healthcare

$19.92+103% 1Y

$19.92

$9.6052 weeks$20.49

Is it growing?

Good

Growing: earnings up +4800% year on year and operating margin widening (+1.5 points).

2 good, 1 neutral

Revenue trend+9% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +9% a year.

Earnings trend+4800% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing faster than revenue, so margins or the share count are helping.

Margin direction+1.5 points operating

Trailing-twelve-month operating margin, 14.7% now against 13.2% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Revenue growth, 3 yearsbetter than 68% of the market

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is AMRX growing?

Amneal Pharmaceuticals, Inc. has grown revenue 10% a year over three years and 8.7% a year over five.

+10%

Revenue growth, 3-year annual rate · Drug Manufacturers - Specialty & Generic median +13% · steady growth, ahead of inflation · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +8.7%
Revenue growth, 5-year rate · +10% over three · growth has picked up over the last three years
Years of annual history on file: 10
Years of annual history on file · FY2016 to FY2025, as filed

Details›